Alexander Navarini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/985675/publications.pdf

Version: 2024-02-01

194 papers

7,021 citations

42 h-index 75 g-index

200 all docs

200 docs citations

200 times ranked

9337 citing authors

#	Article	IF	CITATIONS
1	Interleukin-17E, inducible nitric oxide synthase and arginase 1 as new biomarkers in the identification of neutrophilic dermatoses. Clinical and Experimental Dermatology, 2022, 47, 675-683.	0.6	5
2	European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the <scp>ESSCA^A</scp> and the <scp>EBS^B</scp> working groups of the <scp>ESCD</scp> , and the <scp>GEIDAC^C</scp> . Contact Dermatitis, 2022, 86, 379-389.	0.8	18
3	Clinical Course and Characteristics of Generalized Pustular Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 21-29.	3.3	52
4	Association between allergic sensitization and intestinal parasite infection in schoolchildren in Gqeberha, South Africa. Clinical and Experimental Allergy, 2022, , .	1.4	2
5	Clinical Disease Measures in Generalized Pustular Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 39-50.	3.3	25
6	Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Dermatology, 2022, 238, 967-976.	0.9	4
7	Malignant melanoma in a psoriasis patient after sequential treatment with biologics. Dermatologic Therapy, 2022, 35, e15435.	0.8	4
8	More than words: Itch perception visualized by patients' drawings. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	1
9	Scarce data on skin microbiome in graftâ€versusâ€host disease after allogenic haematopoietic cell transplantation ―a systematic review. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	0
10	HautTief Multidisciplinary Educational Program for Patients with Psoriasis or Atopic Dermatitis: A Randomized Controlled Study. Dermatology, 2022, 238, 1050-1059.	0.9	4
11	Spesolimab treatment for people with flares of generalized pustular psoriasis: a plain language summary of the Effisayilâ,,¢ 1 study. Future Rare Diseases, 2022, 2, .	0.1	O
12	Gender differences in psoriasis: a Swiss online psoriasis survey. Archives of Dermatological Research, 2021, 313, 89-94.	1,1	12
13	Genomic profiling of lateâ€onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 396-402.	1.3	2
14	Mucosal side effects in patients treated with topical imiquimodâ€"A scoping review of the literature. Dermatologic Therapy, 2021, 34, e14355.	0.8	9
15	Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 463-468.e3.	2.0	16
16	Scrotal erythema and geographic tongue subsequent to multikinase inhibiting therapy with Pazopanib. Dermatologic Therapy, 2021, 34, e14629.	0.8	0
17	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1763-1771.	1.2	2
18	National publication productivity in dermatology: an exploratory analysis of contributing factors. International Journal of Dermatology, 2021, 60, e41-e44.	0.5	0

#	Article	IF	CITATIONS
19	Anonymous automated counselling for aesthetic dermatology using a chatbot – an analysis of age― and genderâ€specific usage patterns. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e194-e195.	1.3	2
20	Implementing Medical Chatbots: An Application on Hidradenitis Suppurativa. Dermatology, 2021, 237, 712-718.	0.9	13
21	Global publication productivity in dermatology: a bibliometric description of the past and estimation of the future. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1424-1433.	1.3	16
22	Long-range optical coherence tomography with extended depth-of-focus: a visual feedback system for smart laser osteotomy. Biomedical Optics Express, 2021, 12, 2118.	1.5	11
23	Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open, 2021, 11, e043666.	0.8	48
24	Preâ€ulcerative leishmaniasis mimicking chilblains in a returning traveller from Southern Europe. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e503-e505.	1.3	2
25	Association of sex and systemic therapy treatment outcomes in psoriasis: a twoâ€country, multicentre, prospective, noninterventional registry study*. British Journal of Dermatology, 2021, 185, 1160-1168.	1.4	21
26	Differences in phototherapy among skin diseases and genders in realâ€ife conditions—A retrospective analysis of the cumulative doses, numbers of sessions, side effects and costs in 561 patients. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 464-473.	0.7	2
27	Itch reduction using immersive virtual reality—An experimental pilot study. Dermatologic Therapy, 2021, 34, e15001.	0.8	4
28	Three patients with chronic vulvar pruritus successfully treated with cold atmospheric pressure plasma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1346-1349.	0.4	2
29	NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. Cell, 2021, 184, 4268-4283.e20.	13.5	35
30	Insomnia and other sleep disorders in dermatology patients: A questionnaire-based study with 634 patients. Clinics in Dermatology, 2021, 39, 996-1004.	0.8	7
31	Behandlung von drei Patientinnen mit chronischem vulvÃrem Pruritus mit kaltem AtmosphÃrendruckplasma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1346-1349.	0.4	0
32	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. European Journal of Cancer, 2021, 156, 202-216.	1.3	115
33	Proposition of a severity scale for lichen sclerosus: The "Clinical Lichen Sclerosus Score― Dermatologic Therapy, 2021, 34, e14773.	0.8	6
34	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology, 2021, 237, 166-178.	0.9	17
35	Documentation of psoriasis in routine care – expert consensus on a German data set. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1463-1475.	0.4	8
36	Critical incident reporting over time: a retrospective, descriptive analysis of 5493 cases. Swiss Medical Weekly, 2021, 151, w30098.	0.8	3

#	Article	IF	Citations
37	Complications and cost estimations in herpes zoster – a retrospective analysis at a Swiss tertiary dermatology clinic. Swiss Medical Weekly, 2021, 151, w30081.	0.8	4
38	Smart identification of psoriasis by images using convolutional neural networks: a case study in China. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 518-524.	1.3	30
39	Observerâ€independent assessment of psoriasisâ€affected area using machine learning. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1362-1368.	1.3	27
40	Levocetirizine for the treatment of itch in psoriasis patients: An openâ€label pilot study in a realâ€world setting. Dermatologic Therapy, 2020, 33, e13166.	0.8	6
41	The shortâ€term effect of levocetirizine on quality of life, stress, and depression in itchy psoriasis patients. Dermatologic Therapy, 2020, 33, e13179.	0.8	4
42	Pitfall prayer marks: Recognition and appropriate treatment: A case report and review of literature. Dermatologic Therapy, 2020, 33, e13176.	0.8	5
43	Dermatology and specialty rotations: <scp>COVID</scp> â€19 may reemphasize the importance of internal medicine. Dermatologic Therapy, 2020, 33, e13996.	0.8	2
44	Skin cancer and <scp>COVID < /scp>â€19. Dermatologic Therapy, 2020, 33, e14050.</scp>	0.8	7
45	Internet and social media use in dermatology patients: Search behavior and impact on patientâ€physician relationship. Dermatologic Therapy, 2020, 33, e14098.	0.8	34
46	SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report. Lancet, The, 2020, 396, 598-599.	6.3	41
47	Skin Recovery After Discontinuation of Long-Term Moisturizer Application: A Split-Face Comparison Pilot Study. Dermatology and Therapy, 2020, 10, 1371-1382.	1.4	1
48	Critical incidence reporting in dermatology: a cross-sectional study of 94 cases in a tertiary referral center. Journal of Dermatological Treatment, 2020, , 1-2.	1.1	0
49	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatology, 2020, 156, 1216.	2.0	18
50	National Publication Productivity during the COVID-19 Pandemicâ€"A Preliminary Exploratory Analysis of the 30 Countries Most Affected. Biology, 2020, 9, 271.	1.3	23
51	Co-Occurrence of ANCA-Associated Vasculitis and Sjögren's Syndrome in a Patient With Acromegaly: A Case Report and Retrospective Single-Center Review of Acromegaly Patients. Frontiers in Immunology, 2020, 11, 613130.	2.2	5
52	Contagious itch and disgust during a lecture on ectoparasitic infestations: Two coâ€activated complementary parasite defense systems?. Dermatologic Therapy, 2020, 33, e14456.	0.8	5
53	Occupational skin conditions on the front line: a survey among 484 Chinese healthcare professionals caring for Covidâ€19 patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e354-e357.	1.3	37
54	Hand disinfection in the combat against COVIDâ€19. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e454-e455.	1.3	11

#	Article	IF	CITATIONS
55	When life is an itch: What harms, helps, and heals from the patients' perspective? Differences and similarities among skin diseases. Dermatologic Therapy, 2020, 33, e13606.	0.8	8
56	Pain reduction by dehydrated human amnion/chorion membrane allograft in nondiabetic leg ulcers might be an early indicator of good response: A case series. Dermatologic Therapy, 2020, 33, e13587.	0.8	3
57	Fever with rash in COVIDâ€19: viral exanthema or secondary lesions?. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e464-e465.	1.3	4
58	Performing dermoscopy in the <scp>COVID</scp> â€19 pandemic. Dermatologic Therapy, 2020, 33, e13506.	0.8	7
59	Global Trends in <scp>YouTube</scp> and <scp>Google</scp> Search Activity for Psoriasis and Atopic Eczema: Detecting Geographic Hot Spots, Blind Spots and Treatment Strategies. Dermatologic Therapy, 2020, 33, e13510.	0.8	2
60	Update on COVID â€19 effects in dermatology specialty. Dermatologic Therapy, 2020, 33, e13523.	0.8	13
61	The association between smoking and risk of skin cancer: a meta-analysis of cohort studies. Cancer Causes and Control, 2020, 31, 787-794.	0.8	21
62	Utility and risk of dermatologic medications during the COVID $\hat{a} \in \mathbb{R}^{9}$ pandemic. Dermatologic Therapy, 2020, 33, e13833.	0.8	6
63	Virtual conferences of dermatology during the COVID â€19 pandemic. Dermatologic Therapy, 2020, 33, e13774.	0.8	5
64	The first mention of itch in history? When Egyptologists scratch their heads. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1642-1643.	1.3	3
65	Tumoural soft tissue calcification in Down syndrome: association with heterozygous germline SAMD9 mutation and hyperactive type I interferon signaling. Rheumatology, 2020, 59, e102-e104.	0.9	2
66	The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decisionâ€making tools in psoriasis?. Dermatologic Therapy, 2020, 33, e13276.	0.8	8
67	Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study). Dermatology, 2020, 236, 529-539.	0.9	16
68	Review of biologics in allergic contact dermatitis. Contact Dermatitis, 2020, 83, 179-181.	0.8	15
69	Pruritic and antipruritic colors: An exploratory pilot study. Dermatologic Therapy, 2020, 33, e13447.	0.8	6
70	Sexually transmitted coinfections in patients with anogenital warts $\hat{a} \in \text{``a retrospective analysis of } 196$ patients. JDDG - Journal of the German Society of Dermatology, 2020, 18, 325-332.	0.4	8
71	Safety of the current drug treatments for vitiligo. Expert Opinion on Drug Safety, 2020, 19, 499-511.	1.0	14
72	Twoâ€stage pedicled interpolation flap with wings for reconstruction of combined nasal tip/columella defects. JDDG - Journal of the German Society of Dermatology, 2020, 18, 644-647.	0.4	5

#	Article	IF	CITATIONS
73	Where do we stand as dermatologists in combat with <scp>COVID</scp> â€19. Dermatologic Therapy, 2020, 33, e13638.	0.8	8
74	IL- $36\hat{1}^3$ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. Journal of Clinical Investigation, 2020, 130, 1417-1430.	3.9	33
75	Fiction, Falsehoods, and Few Facts: Cross-Sectional Study on the Content-Related Quality of Atopic Eczema-Related Videos on YouTube. Journal of Medical Internet Research, 2020, 22, e15599.	2.1	37
76	Applications of Generative Adversarial Networks to Dermatologic Imaging. Lecture Notes in Computer Science, 2020, , 187-199.	1.0	2
77	Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 2019, 143, 1021-1026.	1.5	165
78	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Archives of Dermatological Research, 2019, 311, 753-760.	1.1	11
79	Assessment of the impact of sex in intensity, skin flares and central processing of histaminergic itch—A pilot study. Experimental Dermatology, 2019, 28, 1493-1500.	1.4	5
80	Sex differences in the pharmacology of itch therapiesâ€"a narrative review. Current Opinion in Pharmacology, 2019, 46, 122-142.	1.7	9
81	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2313-2318.	1.3	2
82	SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1–Nrf2. Nature Immunology, 2019, 20, 1311-1321.	7.0	39
83	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS ONE, 2019, 14, e0210436.	1.1	26
84	Tofacitinib for the Treatment of Pyoderma Gangrenosum. Clinical Gastroenterology and Hepatology, 2019, 17, 991-993.	2.4	48
85	Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Archives of Dermatological Research, 2019, 311, 421-424.	1.1	36
86	Reply. Journal of Allergy and Clinical Immunology, 2019, 143, 810-811.	1.5	2
87	Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis. Journal of Investigative Dermatology, 2019, 139, 848-858.	0.3	43
88	Thermography: High sensitivity and specificity diagnosing contact dermatitis in patch testing. Allergology International, 2019, 68, 254-258.	1.4	17
89	The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. Journal of Crohn's and Colitis, 2019, 13, 541-554.	0.6	112
90	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 700-708.	1.3	78

#	Article	IF	Citations
91	Perspectives of online surveys in dermatology. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 511-520.	1.3	46
92	Unmet digital health service needs in dermatology patients. Journal of Dermatological Treatment, 2018, 29, 643-647.	1.1	20
93	Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice. Journal of Investigative Dermatology, 2018, 138, 726-728.	0.3	4
94	Acne and hidradenitis suppurativa. British Journal of Dermatology, 2018, 178, 619-631.	1.4	37
95	Therapy response was not altered by HLA w6 status in psoriasis patients treated with secukinumab: a retrospective case series. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e274-e276.	1.3	13
96	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nature Communications, 2018, 9, 25.	5.8	194
97	Expression Patterns of TNFî±, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 347-354.	0.6	44
98	Autoinflammation behind the curtain. British Journal of Dermatology, 2018, 178, 581-582.	1.4	0
99	TNFα and ILâ€17A are differentially expressed in psoriasisâ€like vs eczemaâ€like drug reactions to TNFα antagonists. Journal of Cutaneous Pathology, 2018, 45, 23-28.	0.7	10
100	Wide range of age of onset and low referral rates to psychiatry in a large cohort of acne excoriée at a Swiss tertiary hospital. Journal of Dermatological Treatment, 2018, 29, 277-280.	1.1	14
101	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Reports, 2018, 25, 3564-3572.e4.	2.9	49
102	Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. Nature Communications, 2018, 9, 5075.	5.8	48
103	Generalized pustular psoriasis – a model disease for specific targeted immunotherapy, systematic review. Experimental Dermatology, 2018, 27, 1067-1077.	1.4	56
104	Low immunoglobulin E flags two distinct types of immune dysregulation. Clinical and Experimental Immunology, 2017, 187, 345-352.	1.1	15
105	Secukinumab for Acrodermatitis Continua of Hallopeau. JAMA Dermatology, 2017, 153, 336.	2.0	23
106	A Report of Two Cases of Solid Facial Edema in Acne. Dermatology and Therapy, 2017, 7, 167-174.	1.4	4
107	Genetic architecture of acne vulgaris. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1978-1990.	1.3	39
108	European consensus statement on phenotypes of pustular psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1792-1799.	1.3	269

#	Article	IF	Citations
109	White Scale Sign for Xeroderma. JAMA Dermatology, 2017, 153, 231.	2.0	O
110	Mucocutaneous Ulcerations and Pancytopenia due to Methotrexate Overdose. Case Reports in Dermatology, 2017, 8, 287-293.	0.3	14
111	Swiss S1 guideline for the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1775-1791.	1.3	50
112	Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with Immunodeficiency. Journal of Clinical Immunology, 2017, 37, 707-714.	2.0	11
113	Interruption of Sneddon-Wilkinson Subcorneal Pustulation with Infliximab. Case Reports in Dermatology, 2017, 9, 140-144.	0.3	15
114	A case of tinea incognita and differential diagnosis of figurate erythema. Medical Mycology Case Reports, 2017, 18, 8-11.	0.7	8
115	Rapid Involution of Pustules during Topical Steroid Treatment of Acute Generalized Exanthematous Pustulosis. Case Reports in Dermatology, 2017, 9, 135-139.	0.3	7
116	Skin Manifestations of Inflammatory Bowel Disease. Clinical Reviews in Allergy and Immunology, 2017, 53, 413-427.	2.9	88
117	Acne and Telomere Length: A New Spectrum between Senescence and Apoptosis Pathways. Journal of Investigative Dermatology, 2017, 137, 513-515.	0.3	6
118	Impact of <scp>UVA</scp> on pruritus during <scp>UVA</scp> /B phototherapy of inflammatory skin diseases: a randomized doubleâ€blind study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1208-1213.	1.3	13
119	Allergic Contact Dermatitis. Immunology and Allergy Clinics of North America, 2017, 37, 141-152.	0.7	92
120	Vedolizumab as a successful treatment of CTLA-4–associated autoimmune enterocolitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1043-1046.e5.	1.5	24
121	Generalized Comedones, Acne, and Hidradenitis Suppurativa in a Patient with an FGFR2 Missense Mutation. Frontiers in Medicine, 2017, 4, 16.	1.2	24
122	Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis. Psoriasis: Targets and Therapy, 2017, Volume 8, 7-11.	1.2	6
123	On using Support Vector Machines for the Detection and Quantification of Hand Eczema., 2017,,.		6
124	Apremilast Is Effective in Lichen Planus Mucosae-Associated Stenotic Esophagitis. Case Reports in Dermatology, 2016, 8, 224-226.	0.3	11
125	Targeting CD8+ T cells prevents psoriasis development. Journal of Allergy and Clinical Immunology, 2016, 138, 274-276.e6.	1.5	125
126	Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. Case Reports in Dermatology, 2016, 8, 102-106.	0.3	45

#	Article	IF	Citations
127	The skin and its blossoms—fertile soil for clinical science. Seminars in Immunopathology, 2016, 38, 1-2.	2.8	3
128	Neutrophilic dermatoses and autoinflammatory diseases with skin involvement—innate immune disorders. Seminars in Immunopathology, 2016, 38, 45-56.	2.8	36
129	The continuing evolution of targeted therapy for inflammatory skin disease. Seminars in Immunopathology, 2016, 38, 123-133.	2.8	12
130	Extreme phenotype of epidermal growth factor receptor inhibitor-induced destructive folliculitis. International Journal of Trichology, 2016, 8, 176.	0.1	2
131	Canakinumab in adults with steroidâ€refractory pyoderma gangrenosum. British Journal of Dermatology, 2015, 173, 1216-1223.	1.4	95
132	Homozygous Missense Mutation in <i>IL36RN </i> ii Generalized Pustular Dermatosis With Intraoral Involvement Compatible With Both AGEP and Generalized Pustular Psoriasis. JAMA Dermatology, 2015, 151, 452.	2.0	44
133	Beauty and the Biologic: Artistic Documentation of Scientific Breakthrough in Psoriasis. Case Reports in Dermatology, 2015, 7, 249-252.	0.3	0
134	Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses. Immunity, 2015, 42, 1033-1047.	6.6	190
135	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. Journal of Investigative Dermatology, 2015, 135, 2964-2970.	0.3	89
136	IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. Journal of Allergy and Clinical Immunology, 2015, 135, 1067-1070.e9.	1.5	115
137	Generalized Pustular Eruptions: Time to Adapt the Disease Taxonomy to the Genetic Architecture?. Journal of Investigative Dermatology, 2014, 134, 580-581.	0.3	5
138	Genetic variation in schlafen genes in a patient with a recapitulation of the murine Elektra phenotype. Journal of Allergy and Clinical Immunology, 2014, 133, 1462-1465.e5.	1.5	10
139	IL- \hat{l}^2 Drives Inflammatory Responses to Propionibacterium acnes In Vitro and In Vivo. Journal of Investigative Dermatology, 2014, 134, 677-685.	0.3	178
140	Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris. Nature Communications, 2014, 5, 4020.	5.8	68
141	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. American Journal of Human Genetics, 2014, 94, 790-797.	2.6	153
142	Phototherapy with UVB narrowband, UVA/UVBnb,ÂandÂUVA1 differentially impacts serum 25-hydroxyvitamin-D3. Journal of the American Academy of Dermatology, 2013, 69, 530-536.	0.6	22
143	Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. Journal of Investigative Dermatology, 2013, 133, 1366-1369.	0.3	140
144	Unexplained recurrent fever: when is autoinflammation the explanation?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 285-296.	2.7	35

#	Article	IF	CITATIONS
145	Involvement of Toso in activation of monocytes, macrophages, and granulocytes. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2593-2598.	3.3	67
146	Epidermal IL- $15R\hat{l}\pm$ acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. Journal of Experimental Medicine, 2013, 210, 2105-2117.	4.2	55
147	Canities subita: A reappraisal of evidence based on 196 case reports published in the medical literature. International Journal of Trichology, 2013, 5, 63.	0.1	17
148	Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. Journal of Investigative Dermatology, 2013, 133, 1904-1907.	0.3	107
149	Oral, Esophageal and Cutaneous Lichen Ruber Planus Controlled with Alitretinoin: Case Report and Review of the Literature. Dermatology, 2013, 226, 302-310.	0.9	33
150	Increased Permeability of Cutaneous Lymphatic Capillaries and Enhanced Blood Flow in Psoriatic Plaques. Dermatology, 2013, 227, 118-125.	0.9	12
151	Acutely III Patients in Internal Medicine Departments Want Treatment for Undiagnosed, Symptomatic Skin Conditions. Dermatology, 2012, 225, 115-120.	0.9	7
152	How not to miss autoinflammatory diseases masquerading as urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1465-1474.	2.7	74
153	Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. British Journal of Dermatology, 2012, 167, 1170-1174.	1.4	33
154	Topical Treatment Habits in Psoriasis Patients Receiving Adalimumab. Dermatology, 2012, 224, 228-230.	0.9	3
155	Ror \hat{l}^3 t+ innate lymphocytes and $\hat{l}^3\hat{l}'$ T cells initiate psoriasiform plaque formation in mice. Journal of Clinical Investigation, 2012, 122, 2252-2256.	3.9	456
156	Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection. Journal of Allergy and Clinical Immunology, 2011, 128, 1128-1130.	1.5	123
157	A platelet-mediated system for shuttling blood-borne bacteria to CD8 \hat{i} ±+ dendritic cells depends on glycoprotein GPIb and complement C3. Nature Immunology, 2011, 12, 1194-1201.	7.0	178
158	The Yellow Clod Sign. Archives of Dermatology, 2011, 147, 1350.	1.7	22
159	Low-Dose Excimer 308-nm Laser for Treatment of Lichen Planopilaris. Archives of Dermatology, 2011, 147, 1325.	1.7	37
160	Disfiguring Annular Sarcoidosis Improved by Adalimumab. Case Reports in Dermatology, 2011, 3, 103-106.	0.3	16
161	Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose. Case Reports in Dermatology, 2011, 3, 124-129.	0.3	3
162	Eosinophilia during Psoriasis Treatment with TNF Antagonists. Dermatology, 2011, 223, 311-315.	0.9	32

#	Article	IF	Citations
163	Spitzoid melanoma and micrometastases in two lymph node regions: a critical situation. European Journal of Dermatology, 2011, 21, 229-233.	0.3	2
164	Ecthymatous skin eruption during therapy with cetuximab. European Journal of Dermatology, 2011, 21, 282-283.	0.3	7
165	Longâ€lasting immunity by early infection of maternalâ€antibodyâ€protected infants. European Journal of Immunology, 2010, 40, 113-116.	1.6	18
166	Picture of the Monthâ€"Quiz Case. JAMA Pediatrics, 2010, 164, 1165-6.	3.6	8
167	Antihistamines are superior to topical steroids in managing Human Immunodeficiency Virus (HIV)â€associated papular pruritic eruption. International Journal of Dermatology, 2010, 49, 83-86.	0.5	14
168	Why henry III of navarre′s hair probably did not turn white overnight. International Journal of Trichology, 2010, 2, 2.	0.1	8
169	Syphilitic Pharyngitis. Archives of Dermatology, 2010, 146, 570-2.	1.7	5
170	Minoxidil-Induced Trichostasis Spinulosa of Terminal Hair. Archives of Dermatology, 2010, 146, 1437.	1.7	17
171	Reversal of Canities. Archives of Dermatology, 2010, 146, 103-4.	1.7	6
172	Beneath the Nimbusâ€"The Hair of the Saints. Archives of Dermatology, 2010, 146, 764.	1.7	3
173	Control of Widespread Hypertrophic Lupus Erythematosus with T-Cell-Directed Biologic Efalizumab. Dermatology, 2010, 220, 249-253.	0.9	7
174	Skin Detachment and Regrowth in Toxic Epidermal Necrolysis. Case Reports in Dermatology, 2010, 2, 60-64.	0.3	6
175	Dermoscopy of Pitted Keratolysis. Case Reports in Dermatology, 2010, 2, 146-148.	0.3	17
176	Trauma as Triggering Factor for Development of Melanocytic Nevi. Dermatology, 2010, 220, 291-296.	0.9	18
177	3 Cases of Dissecting Cellulitis of the Scalp Treated With Adalimumab. Archives of Dermatology, 2010, 146, 517-20.	1.7	58
178	Thomas More Syndrome. Dermatology, 2010, 220, 55-56.	0.9	17
179	Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7107-7112.	3.3	93
180	Marie Antoinette Syndrome. Archives of Dermatology, 2009, 145, 656.	1.7	33

#	Article	IF	Citations
181	Melanoma and innate immunity $\hat{a}\in \hat{a}$ Active inflammation or just erroneous attraction?. Seminars in Cancer Biology, 2009, 19, 84-91.	4.3	35
182	Hematopoietic cell–derived interferon controls viral replication and virus-induced disease. Blood, 2009, 113, 1045-1052.	0.6	48
183	Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Annals of Oncology, 2008, 19, 1488-1494.	0.6	23
184	Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse. Gut, 2007, 56, 121-128.	6.1	50
185	MyD88 protects from lethal encephalitis during infection with vesicular stomatitis virus. European Journal of Immunology, 2007, 37, 2434-2440.	1.6	27
186	Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nature Medicine, 2007, 13, 1316-1323.	15.2	54
187	Induced Prion Protein Controls Immune-Activated Retroviruses in the Mouse Spleen. PLoS ONE, 2007, 2, e1158.	1.1	29
188	The prion protein is neuroprotective against retinal degeneration in vivo. Experimental Eye Research, 2006, 83, 1350-1358.	1.2	16
189	Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15535-15539.	3.3	129
190	Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. Journal of Clinical Investigation, 2006, 116, 2456-2463.	3.9	150
191	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Medicine, 2005, 11, 138-145.	15.2	356
192	Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation. European Journal of Immunology, 2005, 35, 738-745.	1.6	149
193	Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology. Journal of Immunology, 2005, 175, 5524-5531.	0.4	2
194	Deliberate removal of T cell help improves virus-neutralizing antibody production. Nature Immunology, 2004, 5, 934-942.	7.0	85